Kinetics of FLT3-ITD VAF during treatment and early FU. (A) For the entire cohort of 157 FLT3-ITD^pos, ITD VAF significantly decreased during therapy and during early FU. FLT3-ITD MRD^neg was achieved in 78% after Cy2, 94% at EOT, and 85% during FU. (B) Patients separated according to NPM1^mut status, demonstrating a significantly higher VAF reduction after Cy2 and higher frequencies of MRD^neg for concurrent NPM1^mut patients. Dx, diagnosis; wt, wild-type.